August 30, 2019
1 min read
Save

DE-128 microshunt reduced IOP, medications in study

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A multicenter study found the DE-128 microshunt implanted intraoperatively with 0.2 mg/mL concentration of mitomycin C effectively reduced IOP in patients with primary open-angle glaucoma not controlled with maximum tolerated glaucoma medications, Santen Pharmaceutical announced in a press release.

The INN-005 prospective, randomized, controlled, single-masked study compared patients who received DE-128 implanted intraoperatively with 0.2 mg/mL concentration of MMC against the standard of care of trabeculectomy with the same concentration of MMC.

Patients implanted with DE-128 experienced a mean diurnal IOP reduction from 21.1 ± 4.9 mm Hg to 14.2 ± 4.4 mm Hg at month 12 compared with a reduction from 21.1 ± 5 mm Hg to 11.2 ± 4.2 mm Hg in the trabeculectomy group, according to the release.

The mean number of glaucoma medications decreased in both groups, from an average of three medications at screening to 0.6 in the DE-128 group and 0.3 in the trabeculectomy group. At month 12, 71.6% of DE-128 patients were medication-free compared with 84.8% in the trabeculotomy arm.

No patients in the DE-128 arm required suture lysis to decrease IOP compared with 52.3% in the trabeculectomy arm. The rate of hypotony was 51.1% in the trabeculectomy arm compared with 30.6% in the DE-128 arm.